Literature DB >> 3495765

Retinoblastoma. Immunohistochemistry and cell differentiation.

M M Rodrigues, B Wiggert, J Shields, L Donoso, D Bardenstein, N Katz, D Friendly, G Chader.   

Abstract

Tumor from eight enucleated eyes was analyzed by immunohistochemistry, using a panel of specific antibodies including interphotoreceptor retinoid-binding protein (IRBP), S-antigen (S-Ag), opsin, neuron-specific enolase (NSE), glial fibrillary acidic protein (GFAP), laminin, and vimentin. In addition, immunoelectron microscopy and enzyme-linked immunosorbent assay (ELISA) for IRBP were performed. Immunohistochemical staining disclosed the most pronounced labeling of tumor cells with NSE and IRBP antibodies. A correlation was found between the degree of tumor differentiation and amount of IRBP, a protein specifically synthesized by photoreceptor cells. Moderate labeling of the better differentiated tumors was also observed with antibodies against S-Ag and focal labeling in a few tumors with opsin antibodies. Anti-GFAP labeling was limited to a smaller number of reactive glial cells and perivascular glial cells. These data indicate the essential neuronal nature of retinoblastoma tumor cells in situ as well as at least partial photoreceptor-like features, as shown by the presence of recognized photoreceptor cell markers (IRBP, S-Ag, opsin). Tissue culture studies using the human Y-79 retinoblastoma cell line also demonstrate that the tumor cells are primitive multipotential retinoblasts capable of at least partial differentiation along neuronal, glial, or pigment epithelial cell lines.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3495765     DOI: 10.1016/s0161-6420(87)33448-7

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  10 in total

1.  Retinoblastoma and retinal astrocytoma: unusual double tumour in one eye.

Authors:  S M Imhof; A C Moll; P Van Der Valk; A Y N Schouten-Van Meeteren
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 2.  Histogenesis of retinoblastoma.

Authors:  J Hungerford
Journal:  Br J Ophthalmol       Date:  1990-03       Impact factor: 4.638

3.  Hypomethylation of the interphotoreceptor retinoid-binding protein (IRBP) promotor and first exon is linked to expression of the gene.

Authors:  A Albini; J Toffenetti; Z Zhu; G J Chader; D M Noonan
Journal:  Nucleic Acids Res       Date:  1990-09-11       Impact factor: 16.971

Review 4.  Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.

Authors:  J F Tarlton; D L Easty
Journal:  Br J Ophthalmol       Date:  1993-12       Impact factor: 4.638

5.  Melanotic ganglioglioma of the pineal region.

Authors:  S J Hunt; P C Johnson
Journal:  Acta Neuropathol       Date:  1989       Impact factor: 17.088

6.  Neuronal and glial properties of a murine transgenic retinoblastoma model.

Authors:  T Kivelä; I Virtanen; D M Marcus; J M O'Brien; J L Carpenter; E Brauner; A Tarkkanen; D M Albert
Journal:  Am J Pathol       Date:  1991-05       Impact factor: 4.307

Review 7.  Expression of developmentally defined retinal phenotypes in the histogenesis of retinoblastoma.

Authors:  F Gonzalez-Fernandez; M B Lopes; J M Garcia-Fernandez; R G Foster; W J De Grip; S Rosemberg; S A Newman; S R VandenBerg
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

8.  Immunohistological characterisation of retinoblastoma and related ocular tissue.

Authors:  J F Tarlton; D L Easty
Journal:  Br J Ophthalmol       Date:  1990-03       Impact factor: 4.638

9.  Immunohistochemical features of the human retina and retinoblastoma.

Authors:  K Yuge; M Nakajima; Y Uemura; H Miki; M Uyama; A Tsubura
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Electrophoretic assessment of aqueous and serum neurone-specific enolase in retinoblastoma and ocular malignant melanoma.

Authors:  B S Shine; J Hungerford; B Vaghela; G A Sheraidah
Journal:  Br J Ophthalmol       Date:  1990-07       Impact factor: 4.638

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.